P1,P5-Di(adenosine-5) pentaphosphate pentasodium salt, >=95% (HPLC), powder

Descriptions

Application

P¹,P⁵-Di(adenosine-5?) pentaphosphate pentasodium salt has been used as:an adenylate kinase (AK) inhibitor in: sarcoma osteogenic (Saos-2) cells mitochondrial lysates during ATP synthesistetramethylrhodamine methyl ester (TMRM) based membrane potential assay chromoplasts

Biochem/physiol Actions

A diadenosine polyphosphate stored in secretory granules of thrombocytes, chromaffin and neuronal cells. After release into the extracellular space, it affects a variety of biological activities in a wide range of target tissues. In the nervous system it acts through various purinergic receptors. It also activates 5′-nucleotidase and inhibits adenosine kinase activity in vitro. Ap5A is metabolized by soluble enzymes in the blood plasma and by membrane-bound ectoenzymes of a number of cell types including endothelial and smooth muscle cells. In cardiac muscle, pM to nM concentrations significantly increase the open-probability of ryanodine-receptor (RyR2) gates, with prolonged action due to slow dissociation from the receptor.

General description

P¹,P⁵-Di(adenosine-5?) pentaphosphate (Ap5A) is a diadenosine polyphosphate, which has a tail-to-tail dimer structure. Ap5A is synthesized in a twostep process involving the formation of adenosine 5?-tetraphosphate (P4A) from the ATP and trimeta-phosphate (P3). In the second step, P4A is converted to Ap5A. The synthesis of Ap5A requires a pH optimum in the range of 7.5 to 8.5 and is modulated by metal ions.

Packaging

2 mg in glass bottle

10, 25, 50 mg in poly bottle

Specifications

Colour	white to yellow-white
Quality Level	200
InChI key	NNMFUJJMJIYTSP-CSMIRWGRSA-I
InChI	1S/C20H29N10O22P5.5Na/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(47-19)1-45-53(35,36)49-55(39,40)51-57(43,44)52-56(41,42)50-54(37,38)46-2-8-12(32)14(34)
Manufacturer	SIGMA-ALDRICH
Form	powder
Assay	≥95% (HPLC)